Zobrazeno 1 - 10
of 432
pro vyhledávání: ''
Autor:
Eugene Zhu, Maria R. Baer, Dietger Niederwieser, Olatoyosi Odenike, Souria Dougherty, Laurie Sherman, Libo Sun, John Mascarenhas, Aleksandra Rizo, Fei Huang, Rami S. Komrokji, Bart L. Scott, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Bruno Martino, Francesca Palandri, Ying Wan, Jacqueline Bussolari, Ronald Hoffman, Faye Feller, Andreas Reiter, Esther Rose
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(26)
PURPOSE Patients with myelofibrosis who are relapsed or refractory (R/R) to Janus-associated kinase inhibitors (JAKis) have poor clinical outcomes including dismal overall survival (OS) that ranges between 13 and 16 months. Imetelstat, a telomerase i
Autor:
Yvonne Suessmuth, Shalini Shenoy, Catherine Bresee, Alison Yu, Amelia Langston, Scott N. Furlan, Andrew C. Harris, Steven E. Bosinger, Muna Qayed, Sungjin Kim, Brandi Bratrude, Maxim Norkin, Audrey G. Tumlin, Jeffrey H. Davis, James Rhodes, John T. Horan, Courtney McCracken, Urvi Kapoor, Alexandria Narayan, Leslie S. Kean, Kayla Betz, Benjamin Watkins, John E. Levine, Bruce R. Blazar, Aleksandra Petrovic, Sung Won Choi, Kayla Cribbin, Michael Grimley, James L.M. Ferrara, Scott Gillespie, Kyle Hebert, Ted Gooley, Marcelo C. Pasquini, Shauna Sinclair, Michael A. Pulsipher, Mourad Tighiouart, Roger Giller, David A. Jacobsohn, Nahal R. Lalefar, Kirk R. Schultz, Christine Duncan, Edmund K. Waller, Gregory A. Yanik, Victor Tkachev, Andre Rogatko, Nosha Farhadfar
Publikováno v:
J Clin Oncol
PURPOSE Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality after HLA-mismatched transplantation. There are no
Autor:
David P. Steensma, Sylvain Thepot, Valeria Santini, Souria Dougherty, Esther Rose, Edo Vellenga, Uwe Platzbecker, Jacqueline Bussolari, Patricia Font, Aleksandra Rizo, Mrinal M. Patnaik, Libo Sun, Fei Huang, Ying Wan, María Díez-Campelo, Koen Van Eygen, Laurie Sherman, Pierre Fenaux, Jun Ho Jang, Helen Varsos, Azra Raza, Faye Feller, Ulrich Germing
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(1), 48-+. AMER SOC CLINICAL ONCOLOGY
PURPOSE Patients with lower-risk (LR) myelodysplastic syndromes (MDS) who are RBC transfusion dependent and have experienced relapse after or are refractory to erythropoiesis-stimulating agent (ESA) have limited treatment options. High telomerase act
Autor:
Hélène Senellart, Sung Bae Kim, Takashi Kojima, Antoine Adenis, Shukui Qin, Peter C. Enzinger, Jaafar Bennouna, Jia Chen, Toshihiko Doi, Jean-Philippe Metges, Ken Kato, Lin Shen, Christelle De La Fouchardiere, Kei Muro, Eric Francois, Toshikazu Moriwaki, Keynote Investigators, S. Peter Kang, Shailaja Suryawanshi, Se-Hoon Lee, Ruixue Wang, Raed Al-Rajabi, Florian Lordick, Paula Ferreira, Gustavo Girotto, Chih-Hung Hsu, Manish A. Shah, Pooja Bhagia
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(35)
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phase III study, we randomly assigned (1:1) 628 patients with advanced/metast
Autor:
Masakazu Toi, Joyce O'Shaughnessy, Investigators, Valentina Guarneri, Ran Wei, Maarten Hulstijn, Irfan Cicin, Mario Campone, Frances M. Boyle, Jens Huober, Patrick Neven, Erika Hamilton, Belen San Antonio, Morihito Okada, Sara M. Tolaney, Andrew M Wardley, Roberto Hegg, Desiree Headley, Stephen R. D. Johnston, Martin Frenzel, Q. Zhang, Priya Rastogi, Zhi Min Shao, Jorge Luis Martinez Rodriguez, Miguel Martín, Javier Cortes, Ian C. Smith, Nadia Harbeck, Joohyuk Sohn, Joanne Cox
Publikováno v:
Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology
Càncer de mama precoç; Teràpia endocrina; Abemaciclib Cáncer de mama precoz; Terapia endocrina; Abemaciclib Early Breast Cancer; Endocrine Therapy; Abemaciclib PURPOSE Many patients with HR+, HER2− early breast cancer (EBC) will not experience
Autor:
Ang Li, Jason C. Chandler, Davey B. Daniel, Félix Couture, Sunil Babu, Vijay Gunuganti, Maen A. Hussein, Robert M. Jotte, Samer Kasbari, Michael McCleod, Edward B. Garon, Justin N. Baker, Nivedita Aanur, Lawrence H. Einhorn, Leora Horn, Ben C. Creelan, Petros Nikolinakos, George P. Keogh, David R. Spigel, Craig Reynolds, Natasha B. Leighl, David M. Waterhouse, George R. Blumenschein
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(33)
PURPOSE Limited data exist on the optimal duration of immunotherapy, including for non–small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-y
Autor:
Nicole Basset-Seguin, Abhishek Joshi, Jessica Bauman, Brett G.M. Hughes, Nicolas Meyer, Rene Gonzalez, Florent Grange, Ramona F. Swaby, P. Zhang, Burak Gumuscu, Josep M. Piulats, Olga Vornicova, Jean-Jacques Grob, Jacob Schachter
Publikováno v:
Journal of Clinical Oncology
PURPOSE Treatment options are limited for patients with recurrent and/or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC); mortality rates exceed 70% in patients with distant metastases. Here, we present the first interim analysis of the R/M
Autor:
Mahmut Gumus, Alexander Luft, Parneet Cheema, Keynote Investigators, Julien Mazieres, M. Catherine Pietanza, Victoria Ebiana, Maya Gottfried, Mirjana Wollner, Francisco Orlandi, Hye Ryun Kim, Solange Peters, Tibor Csőszi, James Chih-Hsin Yang, Yiwen Luo, Charles M. Rudin, Alejandro Navarro, Delvys Rodriguez-Abreu, Gregory P. Kalemkerian, Terufumi Kato, Mark M. Awad
Publikováno v:
J Clin Oncol
PURPOSE Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for
Autor:
Norihiko Ikeda, Katsuo Yoshiya, Isamu Okamoto, Koichi Goto, Takeharu Yamanaka, Nobuyuki Yamamoto, Hiroaki Okamoto, Toshiaki Takahashi, Hideo Saka, Kohei Yokoi, Tsuyoshi Ueno, Tetsuya Mitsudomi, Hiroshi Date, Yuichi Takiguchi, Masahiro Tsuboi, Hirotsugu Kenmotsu, Shinichi Toyooka, Kenji Sugio, Takashi Seto, Haruko Daga
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(19)
PURPOSE To evaluate the efficacy of pemetrexed plus cisplatin versus vinorelbine plus cisplatin as postoperative adjuvant chemotherapy in patients with pathologic stage II-IIIA nonsquamous non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS We
Autor:
Takashi Kojima, Masako Asayama, Yosuke Togashi, Yuichi Mikamoto, Naoki Takahashi, Masashi Wakabayashi, Akihito Kawazoe, Hitomi Tamura, Nami Hirano, Shota Fukuoka, Akihiro Sato, Takeshi Kuwata, Kohei Shitara, Takako Yoshii, Shogo Nomura, Hiroyoshi Nishikawa, Daisuke Kotani, Hiroki Hara
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(18)
PURPOSE This is a phase Ib trial of regorafenib plus nivolumab for gastric and colorectal cancer. PATIENTS AND METHODS Enrolled patients received regorafenib plus nivolumab in a dose-finding part to estimate the maximum tolerated dose. Additional pat